Condition: Locally Advanced Salivary Gland Carcinoma · Sponsor: University of Erlangen-Nürnberg Medical School
This is a prospective registry study based on a standard therapy concept for postoperative simultaneous radiochemotherapy established in Erlangen and elsewhere. The efficacy and tolerability of simultaneous postoperative radiochemotherapy is being investigated. Patients with locally advanced high-grade salivary gland carcinoma after oncological resection are admitted.
This description comes directly from the study's public registry record.
Marlen Haderlein, PD Dr. · 0913185 · marlen.haderlein@uk-erlangen.de
Studiensekretariat · 0913185 · studiensekretariat.ST@uk-erlangen.de
Always discuss trial participation with your own doctor first.
| Erlangen, Universitätsklinikum Strahlenklinik | Erlangen, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06464198